S5 Ep5: FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.